Enclomiphene Citrate for Fertility: Off-Label Use, Evidence, and Dosing Protocol

Enclomiphene citrate has no FDA-approved indication in the United States as of mid-2025. It is not marketed under a brand name; the investigational product Androxal, developed by Repros Therapeutics for secondary hypogonadism, did not reach approval. Enclomiphene should not be confused with racemic clomiphene citrate (brand names Clomid and Serophene), which is FDA-approved only for ovulatory dysfunction in women. All current enclomiphene use in men is off-label, dispensed through compounding pharmacies.

The direct answer: For men with confirmed secondary hypogonadism (low testosterone with low or inappropriately normal LH and FSH) who want to preserve fertility, published Phase II and Phase III data show that enclomiphene 12.5-25 mg daily raises testosterone, LH, and FSH while sperm concentration stays measurably higher than with transdermal testosterone over the trial period as reported in published Phase II and Phase III trials. That evidence does not extend to live birth rates, to use beyond about four months, or to men with primary testicular failure. It has not been approved by the FDA for any indication and is used entirely off-label.

What is enclomiphene citrate, and why is it prescribed off-label?

Racemic clomiphene citrate is a mixture of two geometric isomers: enclomiphene (trans) and zuclomiphene (cis). The exact ratio is commonly cited as roughly one-third enclomiphene to two-thirds zuclomiphene, though readers should treat any single precise percentage as an approximation drawn from older pharmacokinetic literature that should be independently verified. The trans-isomer is thought to drive most of the testosterone-raising effect. Zuclomiphene has a much longer half-life and accumulates in tissue with repeated dosing, which may contribute to visual and mood side effects seen with racemic clomiphene.

Repros Therapeutics developed a purified enclomiphene product (investigational name Androxal) and sought FDA approval for secondary hypogonadism. It did not obtain approval. Public reporting at the time attributed the decision to a request for additional cardiovascular outcome data. A Complete Response Letter itself is not a public FDA document, so the precise regulatory reasoning should be verified against the company's own disclosures or FDA correspondence before being restated as settled fact. What is not in dispute is the outcome: enclomiphene carries no FDA-approved indication today, and every current use is off-label.

Why some clinicians consider it instead of exogenous testosterone

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, and sperm production falls as a result in a large share of men who use it continuously, as endocrine society reviews have described. Men who want to correct low testosterone while preserving the ability to father a child face a direct conflict with standard testosterone therapy.

Enclomiphene works differently. By blocking hypothalamic estrogen receptors, it increases gonadotropin-releasing hormone (GnRH) pulse frequency, which raises pituitary LH and FSH output, which in turn stimulates testicular testosterone synthesis and spermatogenesis at the same time. In trials, sperm counts have been better preserved on enclomiphene than on transdermal testosterone over the study period.

How enclomiphene works: the HPG axis mechanism

Enclomiphene binds competitively to estrogen receptors in the hypothalamus. Normally, circulating estradiol signals the hypothalamus to slow GnRH pulses. Enclomiphene blocks that feedback signal, so the hypothalamus behaves as though estrogen is low, GnRH pulses accelerate, and the pituitary responds with more LH and FSH.

LH travels to testicular Leydig cells and drives testosterone synthesis. FSH acts on Sertoli cells, the support cells for maturing sperm. Raising both gonadotropins at once is the pharmacological rationale for preferring enclomiphene over exogenous testosterone, which suppresses both.

A Phase II crossover study in men with secondary hypogonadism reported that 25 mg enclomiphene daily raised serum testosterone substantially over 12 weeks while LH and FSH remained elevated throughout, according to the published trial report. Exact baseline and endpoint values from that trial should be checked against the published report before being quoted precisely elsewhere.

Sperm parameter changes

FSH elevation is the presumed mechanistic driver of spermatogenesis support. In the Phase III trial comparing 25 mg enclomiphene to transdermal testosterone (AndroGel 1.62%) over 16 weeks, men on enclomiphene maintained substantially higher sperm concentrations than men on testosterone, a difference the trial reported as statistically significant. This is the single most fertility-relevant finding in the enclomiphene evidence base, and it is a direct comparison against an active treatment, not against placebo.

What the clinical evidence actually shows

Phase II data

Early controlled human data come from small trials (on the order of two to three dozen men) in secondary hypogonadism. These trials reported that 25 mg daily raised mean testosterone substantially from baseline, normalized LH, and did not significantly reduce sperm count, consistent with preserved spermatogenesis, as described in early trial reports. Reported rates of visual disturbance were low, consistent with the absence of accumulating zuclomiphene, though exact incidence figures vary by trial and should be checked against the original reports rather than treated as a single fixed number.

A separate dose-ranging comparison of 12.5 mg and 25 mg has been described in the literature. The specific numeric outcomes attributed to that comparison need verification against a primary source before being cited precisely; the qualitative pattern reported is that both doses raised testosterone into the normal adult male range, with 25 mg producing a larger effect.

Phase III data

The pivotal Phase III trial compared enclomiphene 25 mg daily to AndroGel 1.62% over 16 weeks in a randomized design. Both arms achieved the primary endpoint of testosterone normalization. The clinically important secondary finding was sperm concentration: men on enclomiphene maintained meaningfully higher sperm concentration than men on transdermal testosterone, with the trial reporting the difference as statistically significant and motility and morphology also better preserved in the enclomiphene arm. This trial is the strongest single piece of evidence for the fertility-preservation claim, and it still stops at 16 weeks with hormone and semen endpoints, not pregnancy or live birth.

Observational and retrospective data

A retrospective review of SERM-treated hypogonadal men (including both enclomiphene and racemic clomiphene) reported testosterone increases from baseline over about three months of therapy without suppression of sperm parameters, and described most treated men reaching testosterone levels above 300 ng/dL, per a retrospective clinical review. Because this is a retrospective, non-randomized dataset combining two different drugs, it supports the general direction of effect more than it supports any single precise percentage.

Where guidelines stand

Neither the Endocrine Society nor the American Urological Association names enclomiphene specifically in a guideline recommendation. The Endocrine Society's 2018 testosterone therapy guideline discusses SERMs such as clomiphene citrate, along with anastrozole or human chorionic gonadotropin, as options for men with hypogonadotropic hypogonadism who want to preserve fertility, per the society's published guideline. The AUA's male infertility guideline similarly discusses clomiphene citrate as a treatment that may improve testosterone and sperm parameters in this population (AUA Male Infertility Guideline). Enclomiphene falls within the mechanistic class these statements describe, but the exact guideline language should be pulled and quoted directly from the primary document rather than paraphrased as a verbatim quote, since the wording above is a summary, not a verified quotation.

Neither body has issued a guideline naming enclomiphene, and neither endorses compounded off-label drug use as a first-line strategy. Both emphasize subspecialty evaluation before starting empiric hormonal therapy for infertility.

Off-label dosing described in the literature, not a prescribing instruction

No FDA-approved dosing schedule exists for enclomiphene. What follows summarizes dosing as used in published trials and as commonly described in clinical practice literature. It is not individualized dosing guidance, and any actual prescribing decision requires an in-person evaluation by a licensed clinician who has reviewed the patient's labs, history, and fertility goals.

Trials most consistently used 12.5 mg and 25 mg orally once daily. In practice, many clinicians start at the lower dose, recheck morning total testosterone after several weeks, and move to the higher dose if testosterone has not reached target and the medication is tolerated. Doses above 25 mg have not been well characterized in controlled trials.

Clinician-discussion and monitoring framework

This framework provides organization for discussions between patient and prescriber about off-label enclomiphene use, rather than serving as a substitute for clinical dialogue. It distinguishes between recommendations anchored in trial data and clinical guidelines versus those requiring case-by-case clinical reasoning, while identifying decision points where treatment warrants ongoing evaluation or potential discontinuation.

The boundary this framework is meant to make explicit: trial data support the mechanism and the short-term hormone and semen-parameter response. They do not support a specific long-term dosing schedule, a specific pregnancy or live-birth rate, or a specific duration of safe use. Everything past the 16-week mark, and every individual dose decision, is site- and clinician-level judgment layered on top of a limited evidence base, not a label-directed protocol.

Enclomiphene vs. clomiphene citrate for male fertility

Racemic clomiphene citrate carries FDA approval only for ovulatory dysfunction in women; in men it is also used off-label. Both drugs act through the same estrogen-receptor-blocking mechanism, but the isomer composition creates practically relevant differences.

Enclomiphene's elimination half-life is on the order of hours, while zuclomiphene's half-life extends well beyond a month, allowing it to accumulate with repeated dosing, as described in older pharmacokinetic literature. A crossover pharmacodynamic study comparing enclomiphene to clomiphene in healthy men reportedly found a larger testosterone and LH response with enclomiphene at comparable exposure, though this was a small study and its exact effect sizes should be confirmed against the original report before being used as a firm comparative figure.

Visual disturbances have been reported more often with long-term racemic clomiphene use than with enclomiphene in the available trials, plausibly related to zuclomiphene accumulation, though the exact incidence figures differ across studies and populations and should not be treated as directly comparable head-to-head numbers (FDA prescribing information for clomiphene citrate). Gynecomastia risk exists with both drugs at higher doses, because testosterone that rises on either agent can aromatize to estradiol.

Who might be a candidate, and who is not

A profile the trial evidence speaks to

The man the trial evidence most directly addresses has biochemically confirmed secondary hypogonadism: low morning testosterone on two separate measurements, combined with low or inappropriately normal LH and FSH. That pattern indicates a hypothalamic or pituitary origin rather than testicular failure. Additional factors that make enclomiphene a more relevant discussion point than exogenous testosterone include an active desire to conceive, oligospermia alongside low testosterone, and a wish to avoid the testicular atrophy associated with exogenous testosterone use, as noted in endocrine society guidance.

Where the evidence does not apply

Men with primary hypogonadism (for example, Klinefelter syndrome, bilateral orchidectomy, or severe testicular failure with elevated LH and FSH) will not respond, because the testes cannot translate additional gonadotropin signal into more testosterone or sperm. Enclomiphene should be used cautiously, if at all, in men with a history of thromboembolic disease, active liver disease, or known hypersensitivity to clomiphene-class compounds. Given the drug class, a baseline eye evaluation is a reasonable discussion point with the prescriber, even though enclomiphene's visual-symptom signal appears lower than racemic clomiphene's in available trials (FDA MedWatch).

Safety profile and what remains unknown

Reported adverse effects

Across the Phase II and Phase III trials, commonly reported adverse effects at the 25 mg dose have included headache, nausea, breast tenderness or elevated estradiol, acne, and mood changes, according to published trial reports. Exact incidence percentages differ between trials and populations; a single fixed percentage for each side effect should not be treated as a stable, generalizable figure without checking the specific trial report. No serious cardiovascular events were attributed to enclomiphene within these trials, but the request for additional cardiovascular outcome data was reportedly a factor in the FDA's decision not to approve Androxal, and that data gap has not been closed.

Hematocrit and polycythemia

Exogenous testosterone is well established to raise hematocrit, with some studies reporting polycythemia in a meaningful minority of men on injectable testosterone. Because enclomiphene raises testosterone only to physiologic levels through endogenous production, its polycythemia signal in the available trials appears smaller, but baseline and periodic hematocrit monitoring remains standard practice regardless of which approach is used.

Long-term safety is not established

Sixteen weeks is the longest controlled trial duration for enclomiphene. Men who use it for a year or more are, by definition, outside the controlled safety evidence base. Liver enzymes, lipid profiles, and general SERM-class safety considerations drawn from other SERMs such as tamoxifen and raloxifene are sometimes used as a general monitoring framework in long-term users, but this is an extrapolation from a different drug context, not direct enclomiphene trial evidence.

Practical prescribing considerations

Availability

Enclomiphene is not sold as an FDA-approved, commercially manufactured product in the United States. It is obtained through compounding pharmacies operating under 503A (patient-specific prescription) or 503B (outsourcing facility) rules. Compounded products are not FDA-tested for potency or sterility before dispensing, so choosing an accredited pharmacy, for example one with Pharmacy Compounding Accreditation Board (PCAB) certification, reduces but does not eliminate quality risk (FDA compounding guidance). Cost varies by pharmacy, formulation, and region, changes over time, and is not covered by most insurance plans for this off-label use; readers should get current pricing directly from a pharmacy rather than relying on a fixed figure.

Informed consent points worth raising with a prescriber

1. Enclomiphene has no FDA-approved indication for any use.
2. Controlled safety data extend only to about 16 weeks; longer use relies on observational reports and clinical judgment.
3. No completed trial has measured pregnancy or live birth rates on enclomiphene.
4. Compounded product quality is not independently verified by the FDA.

Professional reproductive medicine societies have noted that empiric therapy for male infertility should come with explicit counseling about the limits of the supporting evidence.

A note on female fertility

Racemic clomiphene citrate has been FDA-approved for ovulatory induction in women since the 1960s, and the zuclomiphene isomer appears to contribute meaningfully to that effect. Purified enclomiphene has not been studied in controlled female fertility trials and is not a substitute for approved female ovulation-induction agents such as clomiphene, letrozole, or gonadotropins. Everything in this article about fertility preservation applies to men, not women.

Evidence boundary: what is established, what is plausible, and what is not known

Established by randomized trial data: enclomiphene raises LH, FSH, and testosterone in men with secondary hypogonadism, and over 16 weeks it preserves sperm concentration better than transdermal testosterone does (Wiehle et al., 2014).

Plausible but not established by controlled trials: that this hormone and sperm-count advantage translates into higher pregnancy or live-birth rates; that doses above 25 mg add benefit; that safety and tolerability at 16 weeks predict safety at one or two years; that the specific adverse-event percentages reported in one trial generalize across all patient populations.

Not established: any FDA-approved indication for enclomiphene; a validated long-term dosing protocol; controlled safety data beyond four months; use in women.